Newswise — BETHESDA, Md. – Sept. 19, 2016 – The Association for Molecular Pathology (AMP), the premier global, non-profit organization serving molecular diagnostic professionals, today announced two upcoming events designed to help engage key stakeholders and educate lawmakers about the vital role laboratory developed procedures (LDPs) play in patient care.
U.S. Senate Health, Education, Labor & Pensions (HELP) Hearing: Laboratory Testing in the Era of Precision Medicine (live video broadcast)Witnesses:• David S. Klimstra, MDAttending Pathologist and Chairman, Department of Pathology, James Ewing Alumni Chair in Pathology, Memorial Sloan Kettering Cancer CenterProfessor of Pathology and Laboratory Medicine, Weill Medical College of Cornell University• Brad SpringVice President, Regulatory Affairs and ComplianceBD Life Sciences• Jeff Allen, PhDPresident and CEOFriends of Cancer Research• Karen L. Kaul, MD, PhDChair, Department of Pathology and Laboratory Medicine, Duckworth Family Chair, NorthShore University HealthSystemClinical Professor of Pathology, University of Chicago Pritzker School of MedicineWhen: Tuesday, September 20, 2016 at 10:00 a.m.Where: 430 Dirksen Senate Office Building, Washington DC
Co-hosted Congressional Briefing with the Infectious Diseases Society of America (IDSA) and the American College of Medical Genetics and Genomics (ACMG): What do Cancer Moonshot, PMI, Zika and the CARB National Action Plan All Have in Common?Presenters: Janina A. Longtine, MD, Former AMP President, Angela Caliendo, MD, PhD, Former AMP President, and Sherri Bale, PhD, AMP Member Moderator: Karen L. Kaul, MD, PhD, Former AMP President, Former Editor-in-Chief of The Journal of Molecular DiagnosticsWhen: Tuesday, September 20, 2016 at 3:00 – 4:00 p.m.Where: Capitol Visitor Center Room SVC 208-09, Washington DC
For more information on AMP’s past position statements and letters on LDPs, please visit:• AMP Responds to FDA Report on Oversight of Laboratory Developed Testing Procedures • AMP Submits Written Testimony for Hearing on “Examining the Regulation of Diagnostic Tests and Laboratory Operations” • Congressman Michael Burgess, MD, Speaks at Session on CLIA Modernization of Laboratory Developed Procedures at AMP Annual Meeting• AMP Meets with Senate HELP Committee and Presents a CLIA Modernization Proposal• AMP Submits Written Comments to FDA on Next Generation Sequencing Regulation, Emphasizing Need for Consistent and Proper Performance of Tests• AMP Delivers Oral Comments at FDA Workshop on Optimizing Regulatory Oversight of Next Generation Sequencing Diagnostic Tests• AMP Submits Written Comments to FDA on Proposed Regulation of Laboratory Developed Tests
ABOUT AMPThe Association for Molecular Pathology (AMP) was founded in 1995 to provide structure and leadership to the emerging field of molecular diagnostics. AMP's 2,300+ members practice in the various disciplines of molecular diagnostics, including bioinformatics, infectious diseases, inherited conditions, and oncology. They include individuals from academic and community medical centers, government, and industry; including pathologist and doctoral scientist laboratory directors; basic and translational scientists; technologists; and trainees. Through the efforts of its Board of Directors, Committees, Working Groups, and members, AMP is the primary resource for expertise, education, and collaboration in one of the fastest growing fields in healthcare. AMP members influence policy and regulation on the national and international levels, ultimately serving to advance innovation in the field and protect patient access to high quality, appropriate testing. For more information, visit www.amp.org.
MEDIA CONTACT:Andrew Nobleanoble@amp.org 415-722-2129